CA2339192A1 - Treatment of addiction and addiction-related behavior - Google Patents

Treatment of addiction and addiction-related behavior Download PDF

Info

Publication number
CA2339192A1
CA2339192A1 CA002339192A CA2339192A CA2339192A1 CA 2339192 A1 CA2339192 A1 CA 2339192A1 CA 002339192 A CA002339192 A CA 002339192A CA 2339192 A CA2339192 A CA 2339192A CA 2339192 A1 CA2339192 A1 CA 2339192A1
Authority
CA
Canada
Prior art keywords
use according
medicament
mammal
gvg
abuse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002339192A
Other languages
French (fr)
Other versions
CA2339192C (en
Inventor
Stephen L. Dewey
Jonathan D. Brodie
Charles R. Ashby, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brookhaven Science Associates LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/129,253 external-priority patent/US6057368A/en
Application filed by Individual filed Critical Individual
Publication of CA2339192A1 publication Critical patent/CA2339192A1/en
Application granted granted Critical
Publication of CA2339192C publication Critical patent/CA2339192C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Abstract

The present invention provides a method for changing addiction-related behavior of a mammal suffering from addiction to abused drugs. The method includes administering to the manimal an effective amount of gamma vinylGABA (GVG) or a pharmaceutically acceptable salt thereof, or an enantiomer or a racemic mixture thereof, wherein the effective amount is sufficient to diminish, ihhibit or eliminate behavior associated with craving or use of abused drugs.

Claims (79)

  1. WHAT IS CLAIMED IS:
    Use of gamma vinylGABA (GVG) for preparing a medicament useful for changing addiction-related behavior of a primate suffering from addiction to drugs of abuse by administering said medicament to said primate in an amount sufficient to diminish, inhibit or eliminate behavior associated with craving of drugs of abuse.
  2. 2. The use according to Claim 1, wherein said elimination of behavior associated with craving of drugs of abuse occurs in the absence of an aversive response or appetitive response to GVG.
  3. 3. The use according to Claim 1, wherein said drug of abuse is selected from the group consisting of cocaine, morphine and nicotine.
  4. 4. The use according to Claim 1, wherein said medicament contains GVG
    in an amount of about 100mg/kg to about 300mg/kg.
  5. 5. The use according to Claim 1, wherein said medicament contains GVG
    in an amount from about 150mg/kg to about 300mg/kg.
  6. 6. The use according to Claim 1, wherein said addiction related behavior is conditioned place preference.
  7. 7. Use of gamma vinylGABA (GVG) for preparing a medicament useful for changing addiction-related behavior of a primate suffering from addiction to drugs of abuse by administering said medicament to said primate in an amount sufficient to attenuate the rewarding/incentive effects of drugs of abuse selected from the group consisting of cocaine, morphine and nicotine in the absence of altering rewarding/incentive effects of food in said primate.
  8. 8. The use according to Claim 7, wherein the rewarding/incentive effects of drugs of abuse is attenuated in the absence of an alteration in the locomotor function of said primate.
  9. 9. Use of gamma vinylGABA (GVG) for preparing a medicament useful for ameliorating effects of nicotine addiction in a primate by administering said medicament to said primate in an amount sufficient to reduce nicotine dependency characteristics.
  10. 10. The use according to Claim 9, wherein said medicament contains GVG
    in an amount from about 75mg/kg to about 150mg/kg.
  11. 11. The use according to Claim 9, wherein said medicament contains GVG
    in an amount from about 18mg/kg to about 20mg/kg.
  12. 12. The use according to Claim 9, wherein said nicotine dependency characteristics are reduced in the absence of an aversive response or appetitive response to GVG.
  13. 13. The use according to Claim 9, wherein said nicotine dependency characteristics are reduced in the absence of an alteration in the locomotor function of said primate.
  14. 14. Use of gamma vinylGABA (GVG) for preparing a medicament useful for changing addiction-related behavior of a mammal suffering from addiction to drugs of abuse by administering said medicament to said mammal in an amount sufficient to diminish, inhibit or eliminate behavior associated with craving of drugs of abuse.
  15. 15. The use according to Claim 14, wherein said elimination of behavior associated with craving of drugs of abuse occurs in the absence of an aversive response or appetitive response to GVG.
  16. 16. The use according to Claim 14, wherein said drug of abuse is selected from the group consisting of psychostimuiants, narcotic analgesics, alcohols or nicotine and combinations thereof.
  17. 17. The use according to Claim 14, wherein said drug of abuse is selected from the group consisting of cocaine, nicotine, methamphetamine, ethanol, morphine, heroin and combinations thereof.
  18. 18. The use according to Claim 14, wherein GVG is administered in an amount of about 15mg/kg to about 600mg/kg.
  19. 19. The use according to Claim 14, wherein said addiction related behavior is conditioned place preference.
  20. 20. Use of gamma vinylGABA (GVG) or a pharmaceutically acceptable salt thereof, for preparing a medicament useful for changing addiction-related behavior of a mammal suffering from addiction to drugs of abuse by administering an effective amount of the medicament to the mammal, wherein the effective amount attenuates the rewarding/incentive effects of drugs of abuse selected from the group consisting of psychostimulants, narcotic analgesics, alcohols, nicotine and combinations thereof in the absence of altering rewarding/incentive effects of food in said mammal.
  21. 21. The use according to Claim 20, wherein the rewarding/incentive effects of drugs of abuse is attenuated in the absence of an alteration in the locomotor function of said mammal.
  22. 22. Use of gamma vinylGABA (GVG) or a pharmaceutically acceptable salt thereof for preparing a medicament useful for ameliorating effects of psychostimulant, narcotic analgesic, alcohol or nicotine addiction in a mammal by administering an effective amount of the medicament to the mammal, wherein the effective amount is sufficient to reduce psychostimulant, narcotic analgesic, alcohol or nicotine dependency characteristics.
  23. 23. The use according to Claim 22, wherein GVG is administered in an amount from about 15mg/kg to about 600mg/kg.
  24. 24. The use according to Claim 22, wherein said psychostimulant, narcotic analgesic, alcohol or nicotine dependency characteristics are reduced in the absence of an aversive response or appetitive response to GVG.
  25. 25. The use according to Claim 22, wherein said psychostimulant, narcotic analgesic, alcohol or nicotine dependency characteristics are reduced in the absence of an alteration in the locomotor function of said mammal.
  26. 26. Use of gamma vinylGABA (GVG) or a pharmaceutically acceptable salt thereof, or an enantiomer or a racemic mixture thereof, for preparing a medicament useful for changing addiction-related behavior of a mammal suffering from addiction to drugs of abuse by administering an effective amount of the medicament to the mammal, wherein the effective amount is sufficient to diminish, inhibit or eliminate behavior associated with craving or use of drugs of abuse.
  27. 27. The use according to Claim 26, wherein said elimination of behavior associated with craving of drugs of abuse occurs in the absence of an aversive response or appetitive response to GVG.
  28. 28. The use according to Claim 26, wherein said drug of abuse is selected from the group consisting of psychostimulants, narcotic analgesics, alcohols or nicotine and combinations thereof.
  29. 29. The use according to Claim 26, wherein said drug of abuse is selected from the group consisting of cocaine, nicotine, methamphetamine, ethanol, morphine, heroin and combinations thereof.
  30. 30. The use according to Claim 26, wherein GVG is administered in an amount of about 15mg/kg to about 600mg/kg.
  31. 31. The use according to Claim 26, wherein said addiction related behavior is conditioned place preference.
  32. 32. Use of gamma vinylGABA (GVG) or a pharmaceutically acceptable salt thereof, or an enantiomer or a racemic mixture thereof, for preparing a medicament useful for changing addiction-related behavior of a mammal suffering from addiction to drugs of abuse by administering an effective amount of the medicament to the mammal, wherein the effective amount attenuates the rewarding/incentive effects of drugs of abuse selected from the group consisting of psychostimulants, narcotic analgesics, alcohols, nicotine and combinations thereof in the absence of altering rewarding/incentive effects of food in said mammal.
  33. 33. The use according to Claim 32, wherein the rewarding/incentive effects of drugs of abuse is attenuated in the absence of an alteration in the locomotor function of said mammal.
  34. 34. Use of gamma vinylGABA (GVG) or a pharmaceutically acceptable salt thereof, or an enantiomer or a racemic mixture thereof for preparing a medicament useful for ameliorating effects of psychostimulant, narcotic analgesic, alcohol or nicotine addiction in a mammal by administering an effective amount of the medicament to the mammal, wherein the effective amount is sufficient to reduce psychostimulant, narcotic analgesic, alcohol or nicotine dependency characteristics.
  35. 35. The use according to Claim 34, wherein GVG is administered in an amount from about l5mg/kg to about 600mg/kg.
  36. 36. The use according to Claim 34, wherein said psychostimulant, narcotic analgesic, alcohol or nicotine dependency characteristics are reduced in the absence of an aversive response or appetitive response to GVG.
  37. 37. The use according to Claim 34, wherein said psychostimulant, narcotic analgesic, alcohol or nicotine dependency characteristics are reduced in the absence of an alteration in the locomotor function of said mammal.
  38. 38. Use of a composition that increases central nervous system GABA
    levels for preparing a medicament useful for changing addiction-related behavior of a mammal suffering from addiction to drugs of abuse by administering an effective amount of the medicament to the mammal, wherein the effective amount is sufficient to diminish, inhibit or eliminate behavior associated with craving or use of drugs of abuse.
  39. 39. The use according to Claim 38, wherein said medicament comprises GVG, gabapentin, valproic acid, progabide, gamma-hydroxybutyric acid, fengabine, cetylGABA, topiramate, tiagabine, acamprosate or a pharmaceutically acceptable salt thereof, or an enantiomer or a racemic mixture thereof.
  40. 40. The use according to Claim 38, wherein said elimination of behavior associated with craving of drugs of abuse occurs in the absence of an aversive response or appetitive response to the medicament.
  41. 41. The use according to Claim 38, wherein said drug of abuse is selected from the group consisting of psychostimulants, narcotic analgesics, alcohols or nicotine and combinations thereof.
  42. 42. The use according to Claim 38, wherein said drug of abuse is selected from the group consisting of cocaine, nicotine, methamphetamine, ethanol, morphine, heroin and combinations thereof.
  43. 43. The use according to Claim 38, wherein said addiction related behavior is conditioned place preference.
  44. 44. The use according to Claim 38, wherein said medicament comprises gabapentin administered in an amount of about 500mg to about 2g/day.
  45. 45. The use according to Claim 38, wherein said medicament comprises valproic acid administered in an amount of about 5mg/kg to about 100 mg/kg/day.
  46. 46. The use according to Claim 38, wherein said medicament comprises topiramate administered in an amount of about 50mg to about 1g/day.
  47. 47. The use according to Claim 38, wherein said medicament comprises progabide administered in an amount of about 250mg to about 2g/day.
  48. 48. The use according to Claim 38, wherein said medicament comprises fengabine administered in an amount of about 250mg to about 4g/day.
  49. 49. The use according to Claim 38, wherein said medicament comprises gamma-hydroxybutyric acid administered in an amount of about 5mg/kg to about 100 mg/kg/day.
  50. 50. Use of a composition that increases central nervous system GABA
    levels for preparing a medicament useful for changing addiction-related behavior of a mammal suffering from addiction to drugs of abuse by administering an effective amount of the medicament to the mammal, wherein the effective amount attenuates the rewarding/incentive effects of drugs of abuse selected from the group consisting of psychostimulants, narcotic analgesics, alcohols, nicotine and combinations thereof in the absence of altering rewarding/incentive effects of food in said mammal.
  51. 51. The use according to Claim 50, wherein said medicament comprises GVG, gabapentin, valproic acid, progabide, gamma-hydroxybutyric acid, fengabine, cetylGABA, topiramate, tiagabine, acamprosate or a pharmaceutically acceptable salt thereof, or an enantiomer or a racemic mixture thereof.
  52. 52. The use according to Claim 50, wherein the rewarding/incentive effects of drugs of abuse is attenuated in the absence of an alteration in the locomotor function of said mammal.
  53. 53. Use of a composition that increases central nervous system GABA
    levels for preparing a medicament useful for ameliorating effects of psychostimulant, narcotic analgesic, alcohol or nicotine addiction in a mammal by administering an effective amount of the medicament to the mammal, wherein the effective amount is sufficient to reduce psychostimulant, narcotic analgesic, alcohol or nicotine dependency characteristics.
  54. 54. The use according to Claim 53, wherein said medicament comprises GVG, gabapentin, valproic acid, progabide, gamma-hydroxybutyric acid, fengabine, cetylGABA, topiramate, tiagabine, acamprosate or a pharmaceutically acceptable salt thereof, or an enantiomer or a racemic mixture thereof.
  55. 55. The use according to Claim 53, wherein said medicament comprises gabapentin administered in an amount of about 500mg to about 2g/day.
  56. 56. The use according to Claim 53, wherein said medicament comprises valproic acid administered in an amount of about 5mg/kg to about 100 mg/kg/day.
  57. 57. The use according to Claim 53, wherein said medicament comprises topiramate administered in an amount of about 50mg to about 1g/day.
  58. 58. The use according to Claim 53, wherein said medicament comprises progabide administered in an amount of about 250mg to about 2g/day.
  59. 59. The use according to Claim 53, wherein said medicament comprises fengabine administered in an amount of about 250mg to about 4g/day.
  60. 60. The use according to Claim 53, wherein said medicament comprises gamma-hydroxybutyric acid administered in an amount of about 5mg/kg to about 100mg/kg/day.
  61. 61. The use according to Claim 53, wherein said psychostimulant, narcotic analgesic, alcohol or nicotine dependency characteristics are reduced in the absence of an aversive response or appetitive response to said medicament.
  62. 62. The use according to Claim 53, wherein said psychostimulant, narcotic analgesic, alcohol or nicotine dependency characteristics are reduced in the absence of an alteration in the locomotor function of said mammal.
  63. 63. Use of gamma vinylGABA (GVG) or a pharmaceutically acceptable salt thereof, or an enantiomer or a racemic mixture thereof, for preparing a medicament useful for changing addiction-related behavior of a mammal suffering from addiction to a combination of abused drugs by administering an effective amount of the medicament to the mammal, wherein the effective amount is sufficient to diminish, inhibit or eliminate behavior associated with craving or use of the combination of abused drugs.
  64. 64. The use according to Claim 63, wherein said elimination of behavior associated with craving the combination of abused drugs occurs in the absence of an aversive response or appetitive response to GVG.
  65. 65. The use according to Claim 63, wherein said combination of abused drugs is selected from the group consisting of psychostimulants, narcotic analgesics, alcohols and nicotine.
  66. 66. The use according to Claim 63, wherein said combination is selected from the group consisting of cocaine, nicotine, methamphetamine, ethanol, morphine and heroin.
  67. 67. The use according to Claim 63, wherein said combination is cocaine and heroin.
  68. 68. The use according to Claim 63, wherein GVG is administered in an amount of about 15mg/kg to about 600mg/kg.
  69. 69. The use according to Claim 63, wherein said addiction related behavior is conditioned place preference.
  70. 70. Use of gamma vinylGABA (GVG) or a pharmaceutically acceptable salt thereof, or an enantiomer or a racemic mixture thereof, for preparing a medicament useful for changing addiction-related behavior of a mammal suffering from addiction to a combination of abused drugs selected from the group consisting of psychostimulants, narcotic analgesics, alcohols and nicotine by administering an effective amount of the medicament to the mammal, wherein the effective amount attenuates the rewarding/incentive effects of the combination of abused drugs in the absence of altering rewarding/incentive effects of food in said mammal.
  71. 71. The use according to Claim 70, wherein said combination is selected from the group consisting of cocaine, nicotine, methamphetamine, ethanol, morphine and heroin.
  72. 72. The use according to Claim 70, wherein said combination is cocaine and heroin.
  73. 73. The use according to Claim 70, wherein the rewarding/incentive effects of the combination of abused drugs is attenuated in the absence of an alteration in the locomotor function of said mammal.
  74. 74. Use of gamma vinylGABA (GVG) or a pharmaceutically acceptable salt thereof, or an enantiomer or a racemic mixture thereof for preparing a medicament useful for ameliorating effects of addiction to a combination of abused drugs selected from the group consisting of psychostimulant, narcotic analgesic, alcohol and nicotine in a mammal by administering an effective amount of the medicament to the mammal, wherein the effective amount is sufficient to reduce dependency characteristics of the combination of abused drugs.
  75. 75. The use according to Claim 74, wherein said combination is selected from the group consisting of cocaine, nicotine, methamphetamine, ethanol, morphine and heroin.
  76. 76. The use according to Claim 74, wherein said combination is cocaine and heroin.
  77. 77. The use according to Claim 74, wherein GVG is administered in an amount from about 15mg/kg to about 600mg/kg.
  78. 78. The use according to Claim 74, wherein said dependency characteristics are reduced in the absence of an aversive response or appetitive response to GVG.
  79. 79. The use according to Claim 74, wherein said dependency characteristics are reduced in the absence of an alteration in the locomotor function of said mammal.
CA002339192A 1998-08-05 1999-08-05 Treatment of addiction and addiction-related behavior Expired - Fee Related CA2339192C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US09/129,253 US6057368A (en) 1998-08-05 1998-08-05 Treatment of addiction and addiction-related behavior
US09/129,253 1998-08-05
US09/189,166 1998-11-09
US09/189,166 US6828349B1 (en) 1998-08-05 1998-11-09 Treatment of addiction and addiction-related behavior
US09/209,952 1998-12-11
US09/209,952 US6541520B1 (en) 1998-08-05 1998-12-11 Treatment of addiction and addiction-related behavior
PCT/US1999/017220 WO2000007583A2 (en) 1998-08-05 1999-08-05 Treatment of addiction and addiction-related behavior

Publications (2)

Publication Number Publication Date
CA2339192A1 true CA2339192A1 (en) 2000-02-17
CA2339192C CA2339192C (en) 2009-12-22

Family

ID=27383860

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002339192A Expired - Fee Related CA2339192C (en) 1998-08-05 1999-08-05 Treatment of addiction and addiction-related behavior

Country Status (24)

Country Link
US (4) US6541520B1 (en)
EP (1) EP1102583B1 (en)
JP (1) JP2002522383A (en)
CN (1) CN1172663C (en)
AT (1) ATE328588T1 (en)
AU (1) AU772715B2 (en)
BR (1) BR9912760A (en)
CA (1) CA2339192C (en)
CY (1) CY1105214T1 (en)
CZ (1) CZ2001394A3 (en)
DE (1) DE69931789T2 (en)
DK (1) DK1102583T3 (en)
ES (1) ES2267287T3 (en)
HR (1) HRP20010085A2 (en)
HU (1) HUP0103377A3 (en)
ID (1) ID28916A (en)
IL (1) IL141067A0 (en)
MX (1) MXPA01001268A (en)
NO (1) NO20010539L (en)
NZ (1) NZ509682A (en)
PL (1) PL198789B1 (en)
PT (1) PT1102583E (en)
TW (1) TWI243674B (en)
WO (1) WO2000007583A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101203460B (en) * 2005-05-17 2012-05-23 Wm国际有限公司 Apparatus and method for the non-chemical stabilization of bio-solids

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890951B2 (en) * 1998-08-05 2005-05-10 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
CA2341400A1 (en) * 1998-08-25 2000-03-02 Sepracor, Inc. Methods and compositions employing optically pure s(+) vigabatrin
JP2002527470A (en) * 1998-10-20 2002-08-27 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Anticonvulsant derivatives useful in the treatment of alcoholism, addiction and abuse
BR0008477A (en) * 1999-02-24 2002-01-22 Univ Cincinnati Method to treat an impulse control disorder
MXPA01011014A (en) * 1999-04-30 2003-06-30 Johnson & Johnson Anticonvulsant derivatives useful in treating cocaine dependency.
IT1313585B1 (en) * 1999-07-30 2002-09-09 Neuroscienze S C A R L USE OF GABAB RECEPTOR AGONISTS FOR THE MAINTENANCE THERAPY OF NICOTINE ABSTINENCE IN NICOTINO-EMPLOYEES.
US6395783B1 (en) * 2000-10-23 2002-05-28 Brookhaven Science Associates, Llc Treatment of PCP addiction and PCP addiction-related behavior
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
US20020187996A1 (en) * 2001-05-14 2002-12-12 Dewey Stephen L. Prevention of addiction in pain management
US6462084B1 (en) * 2001-05-14 2002-10-08 Brookhaven Science Associates, Llc Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
UA78211C2 (en) 2001-07-09 2007-03-15 Ortho Mcneil Pharm Inc Salts of fructopyranose derivatives as anticonvulsant
US7041650B2 (en) 2001-07-09 2006-05-09 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivative salts
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7822470B2 (en) * 2001-10-11 2010-10-26 Osypka Medical Gmbh Method for determining the left-ventricular ejection time TLVE of a heart of a subject
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
AU2003213719A1 (en) * 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
US6797707B2 (en) * 2002-03-29 2004-09-28 University Of Florida Antagonists of RF-amide neuropeptides
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
MXPA05000232A (en) 2002-06-21 2005-06-17 Transform Pharmaceuticals Inc Pharmaceutical compositions with improved dissolution.
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
EP3326617A1 (en) 2004-06-12 2018-05-30 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
US20070231268A1 (en) * 2004-11-24 2007-10-04 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060177380A1 (en) * 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060110327A1 (en) * 2004-11-24 2006-05-25 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US8283478B2 (en) 2005-05-20 2012-10-09 Janssen Pharmaceutica Nv Process for preparation of sulfamide derivatives
JP2009507081A (en) * 2005-09-07 2009-02-19 ブレインセルス，インコーポレイティド Regulation of neurogenesis by HDac inhibition
US20070134169A1 (en) * 2005-12-11 2007-06-14 Rabinoff Michael D Methods for smoking cessation or alcohol cessation or other addiction cessation
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
DE102006016990A1 (en) * 2006-04-11 2007-10-18 Hermann, Holger Lars, Dr. Use of baclofen compounds to treat dependence on gamma-hydroxybutyrate or its analogs
EA200870556A1 (en) 2006-05-19 2009-06-30 Янссен Фармацевтика Н.В. COMBINED THERAPY IN THE TREATMENT OF EPILEPSY AND RELATED DISORDERS
US20080103111A1 (en) * 2006-06-21 2008-05-01 Harlan Clayton Bieley Smoking Cessation Treatment with Appetite Suppression
US20100021570A1 (en) * 2006-06-21 2010-01-28 Harlan Clayton Bieley Smoking Cessation Treatment By Reducing Nicotine Cravings, Apetite Suppression, And Altering The Perceived Taste Of Tobacco Smoke
US20090239942A1 (en) * 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
PT2061458E (en) * 2006-09-15 2015-03-11 Univ Minnesota Topiramate compositions and methods for their use
US20090270438A1 (en) * 2006-10-18 2009-10-29 Clive Booles Novel compositions and formulations
JPWO2008090736A1 (en) * 2007-01-23 2010-05-20 公立大学法人名古屋市立大学 Medicament for the prevention and treatment of Alzheimer type dementia
CN106983747A (en) 2007-08-06 2017-07-28 生物系治疗公司 The method for treating dependence
US8883817B2 (en) * 2007-10-18 2014-11-11 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
PE20110060A1 (en) 2008-06-23 2011-01-31 Janssen Pharmaceutica Nv CRYSTALLINE FORM OF (2S) - (-) - N- (6-CHLORO-2,3-DIHYDRO-BENZO [1,4] DIOXIN-2-ILMETHYL) -SULFAMIDE
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
EP3064064A1 (en) * 2009-09-30 2016-09-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
CN102573821A (en) * 2009-09-30 2012-07-11 哈兰·克莱顿·比利 Smoking cessation with body weight maintenance and nutritional supplement
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
WO2011106692A2 (en) * 2010-02-25 2011-09-01 Northwestern University Methods of using (1s, 3s) -3-amino-4-difluoromethylenyl-1-cyclopentanoic acid
US20120046232A1 (en) * 2010-06-22 2012-02-23 Medical University Of South Carolina Compositions and methods for reducing relapse of addictive behavior
EP2826468A1 (en) 2010-12-22 2015-01-21 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
CN103327969A (en) 2010-12-23 2013-09-25 普渡制药公司 Tamper resistant solid oral dosage forms
US20140072936A1 (en) * 2012-09-07 2014-03-13 Patrick D. Herron Method of Tracking Consumption and Associated Effects
EP3446685A1 (en) 2012-11-30 2019-02-27 Acura Pharmaceuticals, Inc. Self-regulated release of active pharmaceutical ingredient
KR101840526B1 (en) 2013-02-05 2018-03-20 퍼듀 퍼머 엘피 Tamper resistant pharmaceutical formulations
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
CA2943728C (en) 2014-03-26 2020-03-24 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release biphasic matrix solid dosage form
EP3643355A1 (en) * 2014-06-03 2020-04-29 Pop Test Abuse Deterrent Technology LLC Drug device configured for wireless communication
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
CN114903006A (en) * 2021-02-09 2022-08-16 中国科学院脑科学与智能技术卓越创新中心 Construction method and application of non-human primate substance addiction model
CN117295710A (en) * 2021-05-05 2023-12-26 思维医学股份有限公司 MDMA enantiomer
CN115386421A (en) * 2022-06-23 2022-11-25 江苏华熙益能生物科技有限公司 Tobacco essence, preparation method and application thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639607A (en) 1970-11-02 1972-02-01 Jack E Phillips Method for treating the tobacco smoking habit
US3960927A (en) 1975-03-18 1976-06-01 Richardson-Merrell Inc. Olefinic derivatives of amino acids
NZ194348A (en) * 1979-07-26 1982-09-14 Merrell Toraude & Co Fluorinated methyl-beta-alanine derivatives and pharmaceutical compositions
GB2133002B (en) 1982-12-30 1986-01-29 Merrell Toraude & Co Process for preparing 4-amino-5-hexenoic acid
GB8311804D0 (en) 1983-04-29 1983-06-02 Merrell Toraude & Co Treatment of seizure disorders and pharmaceutical compositions
US4595697A (en) 1984-03-28 1986-06-17 Merrell Dow Pharmaceuticals Inc. Treatment of seizure disorders and pharmaceutical compositions useful therein
US5189064A (en) * 1985-07-22 1993-02-23 Matrix Technologies, Inc. Treatment of cocaine addiction
DE3882712D1 (en) 1987-10-07 1993-09-02 Matrix Technologies Inc PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF COCOA ADDICTION.
EP0509180A1 (en) * 1991-04-18 1992-10-21 Merrell Dow Pharmaceuticals Inc. Use of GABA-T inhibitors for the treatment of schizophrenia and phencyclidine intoxication
US5189026A (en) * 1991-06-07 1993-02-23 Fractal Laboratories, Inc. Treatment of human diseases involving dysregulation or dysfunction of the nervous system
GB9125615D0 (en) * 1991-12-02 1992-01-29 Wyeth John & Brother Ltd Amines
US5332736A (en) * 1993-11-01 1994-07-26 Ortho Pharmaceutical Corporation Anti-convulsant aroyl aminoacylpyrroles
US5824684A (en) * 1997-02-21 1998-10-20 Synapse Pharmaceuticals International, Inc. Method for treating drug and alcohol addiction
US5760049A (en) * 1997-02-21 1998-06-02 Synapse Pharmaceuticals International, Inc. Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
KR20010031470A (en) 1997-10-28 2001-04-16 둘락 노먼 씨. Method of reducing craving in mammals
JP2002527470A (en) 1998-10-20 2002-08-27 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Anticonvulsant derivatives useful in the treatment of alcoholism, addiction and abuse
BR0008477A (en) 1999-02-24 2002-01-22 Univ Cincinnati Method to treat an impulse control disorder
MXPA01011014A (en) 1999-04-30 2003-06-30 Johnson & Johnson Anticonvulsant derivatives useful in treating cocaine dependency.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101203460B (en) * 2005-05-17 2012-05-23 Wm国际有限公司 Apparatus and method for the non-chemical stabilization of bio-solids

Also Published As

Publication number Publication date
NO20010539L (en) 2001-04-02
EP1102583B1 (en) 2006-06-07
NZ509682A (en) 2004-01-30
US6541520B1 (en) 2003-04-01
US20020037925A1 (en) 2002-03-28
ES2267287T3 (en) 2007-03-01
PT1102583E (en) 2006-10-31
AU5545299A (en) 2000-02-28
EP1102583A2 (en) 2001-05-30
CA2339192C (en) 2009-12-22
ATE328588T1 (en) 2006-06-15
AU772715B2 (en) 2004-05-06
HRP20010085A2 (en) 2002-02-28
TWI243674B (en) 2005-11-21
ID28916A (en) 2001-07-12
CN1172663C (en) 2004-10-27
US6323239B1 (en) 2001-11-27
MXPA01001268A (en) 2003-07-14
HUP0103377A2 (en) 2002-01-28
CY1105214T1 (en) 2010-03-03
WO2000007583A2 (en) 2000-02-17
WO2000007583A3 (en) 2000-09-08
BR9912760A (en) 2001-10-09
US6906099B2 (en) 2005-06-14
DE69931789T2 (en) 2007-05-24
HUP0103377A3 (en) 2003-11-28
CZ2001394A3 (en) 2001-08-15
DE69931789D1 (en) 2006-07-20
IL141067A0 (en) 2002-02-10
PL198789B1 (en) 2008-07-31
JP2002522383A (en) 2002-07-23
PL347912A1 (en) 2002-04-22
NO20010539D0 (en) 2001-01-31
DK1102583T3 (en) 2006-10-09
US6593367B1 (en) 2003-07-15
CN1326342A (en) 2001-12-12

Similar Documents

Publication Publication Date Title
CA2339192A1 (en) Treatment of addiction and addiction-related behavior
JP2002522383A5 (en)
WO2001052851A1 (en) Methods for the treatment of substance abuse
Stromberg The effect of baclofen alone and in combination with naltrexone on ethanol consumption in the rat
US5426120A (en) Pharmaceutical composition containing γ-hydroxybutyric acid or its lactone in the treatment of drug dependence and nutritional disorders
US6890951B2 (en) Treatment of addiction and addiction-related behavior
US6057368A (en) Treatment of addiction and addiction-related behavior
Rosen et al. Buprenorphine: beyond methadone?
Blaine Buprenorphine: an alternative treatment for opioid dependence
IL155574A (en) Use of gamma vinyl gaba for the manufacture of a medicament for the treatment of pcp addiction and pcp addiction-related behavior
Inaba et al. The use of propoxyphene napsylate in the treatment of heroin and methadone addiction
Staquet Analgesic effect of ciramadol in patients with chronic pain
KLEBER et al. Current issues in methadone treatment of heroin dependence
WO2001034161A1 (en) A method of treating substance addiction
Strojek et al. Novel therapeutic agents: Pregabalin in the management of chronic neuropathic pain (NeP): A novel evaluation of flexible and fixed dosing
Fudala LAAM-Pharmacology and Pharmacokinetics, Developmental History, and Therapeutic Considerations
Pycha et al. Buprenorphine: Rapid and slow dose-reductions for heroin detoxification
Pichard-Leandri et al. Evaluation of the side effects related to long term opioid treatment in cancer pain children
Handunge Endogenous Neuropeptide Tyr-MIF-1 Precipitates Abstinence
Vocci Drug Dependence (Addiction) and Its Treatment Frank J. Vocci, Jerome H. Jaffe, and Ram B. Jain
Ng et al. On understanding and treating narcotic dependence: a neuropsychopharmacological perspective
Renault Treatment of Heroin-Dependent Persons with Antagonists: Current Status
Czobor et al. Novel therapeutic agents: A two center double-blind, placebo-controlled randomized study of DOV 220,075 (bicifadine) SR and Tramadol 100 mg in the treatment of post-operative dental pain
Field et al. Novel therapeutic agents: The analgesic actions of pregabalin are mediated through its binding to the α2-δ-1 subunit of voltage-gated calcium channels
Tsaf et al. Sacral epidural analgesia for the relief of postoperative pain in children

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140805